Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Positive interim results from a Phase III trial evaluating the effect of Novartis’ Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in Type 1 spinal muscular atrophy (SMA) patients is expected to make the case stronger for its approval and also its long-term use as a mainstream treatment option. 23 April 2019
Biotechnology
Eli Lilly dipped 1.7% to $113.26 in premarket trading Monday, having dropped as much as 3%, after the company revealed positive results for its Taltz (ixekizumab) and a licensing and research collaboration with Avidity Biosciences. 23 April 2019
Biotechnology
Researchers at the University of Southern California (USC) claim that they have tweaked an immunotherapy molecule and created a cancer treatment with none of the severe side effects typically seen. 23 April 2019
Biotechnology
Merck & Co has picked up another approval in the USA for its anti-PD-1 therapy Keytruda (pembrolizumab), in combination with the TKI therapy Inlyta (axitinib), against advanced renal cell carcinoma (RCC). 23 April 2019
Biotechnology
Pfizer and Eli Lilly have announced mixed top-line results from a Phase III study evaluating tanezumab 2.5mg and 5mg, with only the high dose achieving a statistically-significant improvement for pain and physical function over non-steroidal anti-inflammatory drugs (NSAIDs). 20 April 2019
Biotechnology
A Phase III study of atopic dermatitis candidate nemolizumab, which enrolled people with moderate-to-severe pruritus, has achieved its primary endpoint. 18 April 2019
Biotechnology
California, USA-based OncoSec Medical, a company developing intratumoral cancer immunotherapies, saw its shares leap 32% in pre-market trading after it announced a collaboration with Duke University School of Medicine to evaluate the use of OncoSec's proprietary TAVOPLUS (enhanced interleukin (IL)-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec's novel intratumoral delivery system. 17 April 2019
Biotechnology
On the day that the company announced annual financial results reflecting only marginal growth, German pharma Boehringer Ingelheim’s latest collaboration to bring greater growth in future was announced. 17 April 2019
Biotechnology
Shares in GenSight Biologics were 7% higher with an hour’s trading left on Wednesday. 17 April 2019
Biotechnology
Biotech major Amgen on April 9 announced it had received US Food and Drug Administration approval for its osteoporosis treatment Evenity (romosozumab), nearly three months after the Japan approval. 17 April 2019
Biotechnology
Dutch biotech Kiadis Pharma has entered a definitive agreement to acquire USA-based CytoSen Therapeutics, subject to Kiadis' shareholder approval and customary closing conditions, aiming to create a leader in cell-based cancer immunotherapy. 17 April 2019
Biotechnology
AveXis late Tuesday announced that interim data from its Phase III STR1VE trial of Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in spinal muscular atrophy (SMA) Type 1 showed prolonged event-free survival, an early and rapid increase in CHOP-INTEND scores and significant milestone achievement compared to untreated natural history, consistent with data from the pivotal Phase 1 START trial. 17 April 2019
Biotechnology
Swiss pharma giant Roche this morning reported that, In the first three months of 2019, Group sales rose 8% to 14.8 billion Swiss francs ($14.75 billion), beating the 14.2 billion forecast in a Reuters poll. 17 April 2019
Biotechnology
Flagship Pioneering has added another member to its group of companies. 16 April 2019
Biotechnology
Gilead Sciences (Nasdaq: GILD) and drug discovery start-up insitro have entered into a strategic collaboration to discover and develop therapies for patients with non-alcoholic steatohepatitis (NASH). 16 April 2019
Biotechnology
The European Medicines Agency has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of immune-mediated conditions (caused by the body’s defence system not working properly) and problems with the heart and blood vessels with the medicine, including fatal cases. 16 April 2019
Biotechnology
Advanced delivery technologies firm Catalent has entered into a definitive agreement to acquire Paragon Bioservices, a leading viral vector development and manufacturing partner for gene therapies. 16 April 2019
Biotechnology
Following swiftly on its US regulatory approval last week, biotech major Amgen yesterday announced that its Evenity (romosozumab-aqqg) is now available for shipment to wholesalers in the USA. 16 April 2019
Biotechnology
Novartis has submitted for approval in the USA for brolucizumab, known internally as RTH258, for the treatment of wet age-related macular degeneration (AMD). 16 April 2019
Biotechnology
The Janssen drug Balversa (erdafitnib) has become the first FGFR kinase inhibitor to receive US Food and Drug Administration (FDA) approval. 15 April 2019
All news
Biotechnology
Belgium’s largest drugmaker UCB on Friday announced the successful closing of the sale, divestment and license of its mature neurology and allergy portfolio in China to CBC Group, Asia’s largest healthcare-focused asset management group, and Mubadala Investment Company for an enterprise value of $680 million, first announced earlier this year. 30 November 2024
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze